IZUMO4

Across TCGA pan-cancer cohorts, IZUMO4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IZUMO4 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IZUMO4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IZUMO4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC and UCEC are the cancer types where IZUMO4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.079	0.553	.003	18	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

IZUMO4–LIHC (DFS)

Open the LIHC breakdown →